The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 31 January 2019 that it had recommended granting marketing authorization for the adalimumab biosimilars Idacio and Kromeya.
- INICIO
-
Genéricos
Novedades
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
Investigación
- Evaluation of pharmaceutical equivalency of manufactured generic drugs in UAE
- New insights into the amount of R & D for new uses of generic drugs
- Pricing and reimbursement of medicines in Canada
- Medicines pricing conditions in Italy and Brazil: comparison of regulations
-
Biosimilares
Novedades
- China approves tocilizumab copy biological BAT1806
- FDA accepts application for denosumab biosimilar GP2411
- EMA accepts application for ustekinumab biosimilar AVT04
- Ranibizumab biosimilar Ximluci and Amelivu to launch in the UK and South Korea
Investigación
- A global overview of manufacturers of follow-on biologicals
- Study supports increased development of insulin biosimilars
- Perspectiva y papel de los farmacéuticos hospitalarios de Malasia en la promoción del uso de biosimilares
- Survey demonstrates US pharmacist biosimilar knowledge gaps
- MORE EDITORIAL SECTIONS
- Search
Post your comment